Answer to Question 1
Correct Answer: 1
Rationale 1: Lisinopril therapy can increase the risk of hyperkalemia because it is a potassium-sparing drug. Clients with heart failure are at higher risk.
Rationale 2: Lisinopril therapy does not increase the risk of hyponatremia.
Rationale 3: Lisinopril therapy does not increase the risk of hypernatremia.
Rationale 4: Lisinopril therapy does not increase the risk of hypokalemia, but of hyperkalemia.
Global Rationale: Lisinopril therapy can increase the risk of hyperkalemia because it is a potassium-sparing drug. Clients with heart failure are at higher risk. Lisinopril therapy does not increase the risk of hyponatremia, hypernatremia, or hypokalemia.
Answer to Question 2
Correct Answer: 3
Rationale 1: Use of fish oil supplements is not contraindicated with lisinopril therapy. Fish oil supplements might be beneficial to the hypertensive client.
Rationale 2: Use of calcium supplements is not contraindication in lisinopril therapy.
Rationale 3: Use of potassium supplements is contraindicated with lisinopril therapy because of the risk of hyperkalemia. Lisinopril is a potassium-sparing drug.
Rationale 4: Use of multiple vitamins is not contraindicated in lisinopril therapy.
Global Rationale: Use of potassium supplements is contraindicated with lisinopril therapy because of the risk of hyperkalemia. Lisinopril is a potassium-sparing drug. Use of fish oil supplements is not contraindicated with lisinopril therapy. Fish oil supplements might be beneficial to the hypertensive client. Use of calcium supplements and a multivitamin is not contraindicated in lisinopril therapy.